arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GYRE THERAPEUTICS, INC.

GYRE
$7.43 ▼ -0.08 (-1.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
50
Health
Fair
Neutral
auto_awesome

Analytical Summary

GYRE THERAPEUTICS, INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $747.7M
Dividend Yield —
Revenue Growth -2.1% ↘
Op. Margin -49.3% ↘
ROIC -13.2% ↘
FCF / Share $-0.17 ↘
Trailing P/E —
Price / Book 7.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$29.11M
↓ -2.1% —
Net Income Profit after all expenses
$-18.58M
↓ -88.5% —
Operating Margin Operating profit as % of sales
-49.3%
↓ -18.8% 56th
FCF / Share Free cash flow per share
$-0.17
↓ -92.7% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —

Health Breakdown

Profitability ↑
47
Returns
66
Cash Quality
21

Dividend History

Dividend / share · sourced from SEC filings
$0.24 Latest / share
-83.2% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters